Combined administration of integrin receptor antagonists for anti-angiogenic therapy

Abstract

The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an αvβ3 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).

1 . A pharmaceutical formulation comprising an αvβ3 antagonist, an α2β1 antagonist, and a pharmaceutically acceptable carrier. 
     
     
         2 . The pharmaceutical formulation of  claim 1 , comprising echistatin and VP12 (ECL12). 
     
     
         3 . An article of manufacture comprising an αvβ3 antagonist, an α2β1 antagonist, and instructions for administering an effective amount of the αvβ3 antagonist and an effective amount of the α2β1 antagonist to a subject. 
     
     
         4 . A method of inhibiting angiogenesis in a subject, comprising administering an effective amount of an αvβ3 antagonist in combination with an effective amount of an α2β1 antagonist to the subject. 
     
     
         5 . The method of  claim 4 , comprising administering echistatin and VP12 (ECL12) to the subject. 
     
     
         6 . The method of  claim 4 , wherein the method further inhibits tumor invasion. 
     
     
         7 . The method of  claim 4 , wherein the method inhibits the growth of solid tumors. 
     
     
         8 . The method of  claim 4 , further comprising the administration of an effective amount of an antiproliferative. 
     
     
         9 . The method of  claim 4 , further comprising the administration of an effective amount of radiation therapy. 
     
     
         10 . A method of inhibiting angiogenesis in a subject, comprising administering an effective amount of echistatin in combination with an effective amount of VP12 (ECL12) to the subject. 
     
     
         11 . The method of  claim 10 , wherein the method further inhibits tumor invasion. 
     
     
         12 . The method of  claim 10 , wherein the method further inhibits the growth of solid tumors. 
     
     
         13 . The method of  claim 10 , further comprising the administration of an effective amount of an antiproliferative. 
     
     
         14 . The method of  claim 10 , further comprising the administration of an effective amount of radiation therapy. 
     
     
         15 . A method of inhibiting the growth of a solid tumor in a subject, comprising administering an effective amount of echistatin in combination with an effective amount of VP12 (ECL12) to the subject. 
     
     
         16 . The method of  claim 15 , wherein the method further inhibits tumor invasion. 
     
     
         17 . The method of  claim 15 , further comprising the administration of an effective amount of an antiproliferative. 
     
     
         18 . The method of  claim 15 , further comprising the administration of an effective amount of radiation therapy. 
     
     
         19 . A method of inhibiting tumor invasion in a subject, comprising administering an effective amount of echistatin in combination with an effective amount of VP12 (ECL12) to the subject. 
     
     
         20 . The method of  claim 19 , wherein the method inhibits the growth of solid tumors. 
     
     
         21 . The method of  claim 19 , further comprising the administration of an effective amount of an antiproliferative. 
     
     
         22 . The method of  claim 19 , further comprising the administration of an effective amount of radiation therapy.